MedTrace Logo

Intestinal Microbiota and Treatment of GD

NCT03433352 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2018-02-14

No results posted yet for this study

Summary

Graves' disease is an organ-specific autoimmune disease in which both genetic predisposition and environmental factors serve as disease triggers. Many studies have indicated that alterations in the gut microbiota are important environmental factors in the development of inflammatory and autoimmune diseases. Investigators systematically performed a comparative analysis of the gut microbiota in GD patients and healthy controls and analyse the relationship between intestinal microbiota and GD drug therapy.

Conditions

  • Microbiota

Interventions

DRUG

Methimazole Pill

Patients who developed GD received methimazole treatment

DRUG

Propylthiouracil Pill

Patients who developed GD received propylthiouracil treatment

Sponsors & Collaborators

  • First Affiliated Hospital of Harbin Medical University

    lead OTHER

Principal Investigators

  • Yunwei Wei · First Affiliated Hospital of Harbin Medical University

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-12-23
Primary Completion
2018-12-23
Completion
2019-12-20
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03433352 on ClinicalTrials.gov